JGC
NAUT icon

J. Goldman & Co’s Nautilus Biotechnolgy NAUT Stock Holding History

J. Goldman & Co’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-178,067
Closed -$1.93M – 497
2020
Q4 		$1.93M Sell
178,067
-40,481
-19% -$426K 0.1% 195
2020
Q3 		$2.36M Buy
+218,548
New +$2.33M 0.16% 157

Other funds holding NAUT

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

J. Goldman & Co's NAUT Position: Q1 2021 in Review

J. Goldman & Co sold out of Nautilus Biotechnolgy (NAUT) in Q1 2021, closing a stake of 178,067 shares — an estimated $1.93M sold.

J. Goldman & Co first reported a position in NAUT in Q3 2020 and held it in 2 quarters. The position peaked at $2.36M in Q3 2020. 44 funds tracked by Wall St. Rank hold NAUT as of Q1 2021.

  • J. Goldman & Co reported no remaining Nautilus Biotechnolgy position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 178,067 Nautilus Biotechnolgy shares in Q1 2021, an estimated $1.93M.
  • J. Goldman & Co first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 2 quarters.
  • J. Goldman & Co's Nautilus Biotechnolgy position peaked at $2.36M in Q3 2020.
  • 44 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.